Department of Urinary Surgery, Yidu Central Hospital of Weifang City, Weifang, China.
Department of Vascular Surgery, Yidu Central Hospital of Weifang City, Weifang, China.
Genes Genomics. 2021 Nov;43(11):1317-1325. doi: 10.1007/s13258-021-01108-w. Epub 2021 May 4.
Bladder cancer is a common urinary cancer, and most patients suffer tumor recurrence after surgery. Identifying more prognostic biomarkers is an essential task for precious treatment.
To evaluate the expression and clinical significance of GPR123, Angiotensin-I a type of adhesion G protein-coupled receptors (aGPCRs), in bladder cancer.
The expressions of GPR123 in two retrospective cohorts comprised of 150 and 56 patients with bladder cancer respectively, were detected with and immunohistochemistry (IHC). Moreover, GPR123 mRNAs in 11 non-muscle-invasive bladder cancers (NMIBCs) and 11 muscle-invasive bladder cancers (MIBCs) were detected with qRT-PCR. The correlation between GPR123 and the clinicopathological characters was estimated by Chi-square test. The significance of GPR123 and other clinicopathological characters in recurrence and prognosis of bladder cancer was evaluated by univariate and multivariate analyses.
GPR123 was mainly expressed in the cell membrane of bladder cancer. The percentages of high GPR123 expression in NMIBC and MIBC were 38.32 and 55.81 % in cohort 1, and 16.00 and 43.90 % in cohort 2. With qRT-PCR and IHC, we showed that GPR123 expression in MIBC was significantly higher than that in NMIBC. GPR123 was significantly associated with T and M stage of bladder cancer. GPR123 expression was all correlated with recurrence (disease-free survival rate), and prognosis (overall survival rate). High GPR123 expression was identified as independent biomarker indicating easier recurrence and poorer prognosis.
GPR123 was an independent biomarker of bladder cancer for recurrence and prognosis, indicating that GPR123 detection with IHC after operation could help find the high-risk patients and direct the post-operational surveillance.
膀胱癌是一种常见的泌尿系统癌症，大多数患者在手术后会出现肿瘤复发。鉴定更多的预后生物标志物是进行宝贵治疗的关键任务。
评估 GPR123，血管紧张素-1 型黏附 G 蛋白偶联受体（aGPCRs）在膀胱癌中的表达及其临床意义。
使用免疫组织化学（IHC）检测两个包含 150 例和 56 例膀胱癌患者的回顾性队列中的 GPR123 表达情况。此外，使用 qRT-PCR 检测 11 例非肌肉浸润性膀胱癌（NMIBC）和 11 例肌肉浸润性膀胱癌（MIBC）中的 GPR123 mRNA。采用卡方检验评估 GPR123 与临床病理特征之间的相关性。采用单因素和多因素分析评估 GPR123 与其他临床病理特征在膀胱癌复发和预后中的意义。
GPR123 主要表达在膀胱癌的细胞膜上。在队列 1 中，NMIBC 和 MIBC 中高 GPR123 表达的比例分别为 38.32%和 55.81%，在队列 2 中分别为 16.00%和 43.90%。通过 qRT-PCR 和 IHC，我们表明 MIBC 中的 GPR123 表达明显高于 NMIBC。GPR123 与膀胱癌的 T 和 M 分期显著相关。GPR123 的表达均与复发（无病生存率）和预后（总生存率）相关。高 GPR123 表达被确定为预示更易复发和更差预后的独立生物标志物。
GPR123 是膀胱癌复发和预后的独立生物标志物，表明手术后使用 IHC 检测 GPR123 有助于发现高危患者，并指导术后监测。
